Today, the FDA approved elotuzumab (Empliciti), an injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies.
Today, the FDA approved elotuzumab (Empliciti), an injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies.
The approval was based on data from the ELOQUENT-3 trial, a randomized, open-label, phase 2 study that enrolled 117 patients and found that EPd demonstrated a benefit in patients with relapsed or refractory multiple myeloma. Patients were randomized in a 1:1 ratio to receive either EPd (n = 60) or pomalidomide and dexamethasone (n =57) in 28-day cycles until disease progression or unacceptable toxicity. The study found that the combination treatment doubled both the median progression-free survival and overall response rate versus pomalidomide and dexamethasone alone.
“Empliciti plus pomalidomide and dexamethasone has been proven to extend the time that certain patients live without disease progression, giving healthcare professionals an effective new tool to tackle this relentless cancer,” said Joseph Eid, MD, senior vice president and head of medical, Bristol-Myers Squibb.
The trial specifically demonstrated that the combination treatment reduced the risk of disease progression by 46% (hazard ratio: 0.54; 95% CI: 0.34 to 0.86, P = 0.0078). This finding in turn led to a median progression-free survival of 10.25 months compared with 4.67 months for pomalidomide and dexamethasone alone.
Researchers found that serious adverse events were reported in 22% of the patients treated with EPd, and in 15% of patients treated with pomalidomide and dexamethasone. Treatment discontinuation due to adverse events occurred in 5% of patients enrolled in the EPd arm, compared with 1.8% in the pomalidomide and dexamethasone arm.
“This new regimen of elotuzumab combined with pomalidomide and dexamethasone not only extended the time to disease progression versus a standard of care but also doubled the response rate in some patients whose prior treatments had failed them,” said Paul Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute.
Following priority review by the FDA, EPd is the first triplet combination to be approved on a randomized clinical trial using pomalidomide and dexamethasone as a comparator.
Dr Guru Sonpavde: Nivolumab Plus Gemcitabine-Cisplatin Holds Promise in Urothelial Cancer
November 30th 2023Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve outcomes for the first time in decades.
Read More
The FDA has approved pembrolizumab (Keytruda) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Read More
Addressing Financial Toxicity With Navigators and Better Conversations Around Decision Making
June 5th 2018Financial toxicity impacts a lot more than a patient's finances—it leads to nonadherence and poorer health outcomes. Financial navigators are increasingly being used to be proactive about addressing high healthcare costs and the resulting financial toxicity.
Listen
Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer
November 1st 2023The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.
Read More